# Troy Kanji

> Troy Kanji is an analyst at Boost VC, a pre-seed venture capital firm in San Mateo focused on deep tech investments. With a background in molecular biology from Brown University—where he researched ALS using Drosophila genetics—he bridges the worlds of science and finance. Before Boost VC, he cut his teeth at Trinity Life Sciences, F-Prime Capital (genomics), and Castle Island Ventures (crypto), building a unique cross-disciplinary lens. He's also co-founder and board member of Revalia Bio, a Yale spinout revolutionizing drug development with human data trials using donated organs.

- **Role:** Analyst at Boost VC
- **Organizations:** Boost VC, Revalia Bio, Trinity Life Sciences, F-Prime Capital, Castle Island Ventures, Brown University
- **Education:** Bachelor of Science, Brown University
- **Known for:** Co-founder and board member of Revalia Bio, which raised $14.5M seed round and grew revenue 4x with top 10 pharma customers, Part of Boost VC's $87 million Fund IV deployment across 400+ deep tech companies, Contributed to research on TDP-43 evolution and molecular mechanisms of neurodegenerative disease at Brown University

## Career timeline

- **2019-2023** — Conducted research on TDP-43 proteinopathy in ALS-focused Drosophila genetics lab at Brown University
- **~2021** — Investment Analyst Intern at Castle Island Ventures, researching cryptocurrency adoption and DeFi
- **~2022** — Investment Analyst Intern at F-Prime Capital, evaluating next generation sequencing market investments
- **~2023** — Associate Consultant at Trinity Life Sciences
- **2024** — Joined Boost VC as Analyst
- **2024** — Co-founded and joined board of Revalia Bio, a Yale spinout
- **2025** — Part of Boost VC team that led Radiant Nuclear's $300M Series D round

## Achievements

- Co-founder and board member of Revalia Bio, which raised $14.5M seed round and grew revenue 4x with top 10 pharma customers
- Part of Boost VC's $87 million Fund IV deployment across 400+ deep tech companies
- Contributed to research on TDP-43 evolution and molecular mechanisms of neurodegenerative disease at Brown University
- Helped evaluate and execute investments across biotechnology, nuclear energy, genomics, and cryptocurrency sectors
- Part of team that led Radiant Nuclear's $300M Series D, one of the largest nuclear energy startup rounds

## Latest updates

- **2025-12** — Boost VC led Radiant Nuclear's $300M Series D round for portable nuclear microreactors
- **2025** — Revalia Bio achieved 4x revenue growth with multiple top 10 pharma customers onboard
- **2024** — Boost VC announced $87 million Fund IV to power deep tech across nuclear, genetics, space, and more

## Links

- LinkedIn: https://www.linkedin.com/in/troy-kanji/
- Twitter/X: https://twitter.com/TroyKanji

---

Profile page: https://yespress.io/troy-kanji
Published by YesPress — https://yespress.io
Last updated: 2026-05-02